Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.37 |
| ▸ | CDK2 | P24941 | 8/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 8/20 | 0.37 |
| ▸ | CDK5R1 | Q15078 | 8/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | PDE8A | O60658 | 3/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | APAF1 | O14727 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29491131 | 1.00 | MAPK14 (0.40) | MAPK14SMN1; SMN2CCNA2CDK2CCNA1 | |
| SCHEMBL29491141 | 0.85 | SMN1; SMN2 (0.37) | MAPK14SMN1; SMN2CCNA2CDK2CCNA1 | |
| SCHEMBL22650407 | 0.83 | L3MBTL1 (0.37) | MAPK14SMN1; SMN2CCNA2CDK2CCNA1 | |
| SCHEMBL22650403 | 0.82 | MAPK14 (0.35) | MAPK14SMN1; SMN2CCNA2CDK2CCNA1 | |
| SCHEMBL22650364 | 0.79 | CDK4 (0.37) | MAPK14SMN1; SMN2CCNA2CDK2CCNA1 | |
| SCHEMBL22650372 | 0.79 | SMN1; SMN2 (0.36) | MAPK14SMN1; SMN2CCNA2CDK2CCNA1 | |
| SCHEMBL22650362 | 0.79 | CDK4 (0.36) | CDK2CDK1 | |
| SCHEMBL22650360 | 0.78 | SMN1; SMN2 (0.41) | SMN1; SMN2CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL22650746 | 0.77 | SMN1; SMN2 (0.45) | SMN1; SMN2CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL29491171 | 0.77 | SMN1; SMN2 (0.45) | SMN1; SMN2CCNA2CDK2CCNA1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281487-A1 | CDK INHIBITORS | GENENTECH, INC. (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250275972-A1 | CDK INHIBITORS | GENENTECH, INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-20250275971-A1 | CDK INHIBITORS | GENENTECH, INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-12285429-B2 | CDK inhibitors | GENENTECH, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-20250064806-A1 | CDK INHIBITORS | GENENTECH, INC. | 2025-02-27 | — | — | US | disclosed |
| US-20240066031-A1 | CDK INHIBITORS | GENENTECH, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240066031-A1 | CDK INHIBITORS | GENENTECH, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240066031-A1 | CDK INHIBITORS | GENENTECH, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240033264-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2024-02-01 | — | — | US | disclosed |
| US-20230174512-A1 | CDK INHIBITORS | GENENTECH, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174512-A1 | CDK INHIBITORS | GENENTECH, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174512-A1 | CDK INHIBITORS | GENENTECH, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20220296595-A1 | CDK INHIBITORS | GENENTECH, INC. | 2022-09-22 | — | — | US | disclosed |
| WO-2021226140-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2021-11-11 | — | — | WO | disclosed |
| WO-2020224568-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281487-A1 | CDK INHIBITORS | CDK6, CDK9, CDKL1 | MAPK14 238/4885SMN1; SMN2 2041/4885CCNA2 41/4885 |
| US-20240033264-A1 | CDK INHIBITORS | CDK9, CDKL1, CDK3 | MAPK14 196/4885SMN1; SMN2 2631/4885CCNA2 41/4885 |
| US-20240066031-A1 | CDK INHIBITORS | CDK9, CDKL1, CDK3 | MAPK14 196/4885SMN1; SMN2 2631/4885CCNA2 41/4885 |
| US-20250064806-A1 | CDK INHIBITORS | CDK9, CDK6, CDK3 | MAPK14 190/4885SMN1; SMN2 2777/4885CCNA2 39/4885 |
| US-12285429-B2 | CDK inhibitors | CDK9, CDK3, CDKL1 | MAPK14 200/4885SMN1; SMN2 2470/4885CCNA2 39/4885 |
| US-20250275972-A1 | CDK INHIBITORS | CDK9, CDK6, CDK3 | MAPK14 190/4885SMN1; SMN2 2777/4885CCNA2 39/4885 |
| US-20220296595-A1 | CDK INHIBITORS | CDKL1, CDK9, CDK6 | MAPK14 170/4885SMN1; SMN2 2350/4885CCNA2 41/4885 |
| US-20230174512-A1 | CDK INHIBITORS | CDK9, CDKL1, CDK3 | MAPK14 196/4885SMN1; SMN2 2631/4885CCNA2 41/4885 |
| US-20250275971-A1 | CDK INHIBITORS | CDK6, CDK9, CDKL1 | MAPK14 238/4885SMN1; SMN2 2041/4885CCNA2 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.